Toll-like receptor 9 agonist inhibits ER α-mediated transactivation by activating NF-κB in breast cancer cell lines

Oncology Reports

Volumn 22, Issue 4, 2009, Pages 935-941

  Qiu, Jianming ^a,b   Wang, Xiaojian ^a   Guo, Xinhai ^b   Zhao, Chenyin ^b   Wu, Xuhui ^b   Zhang, Yongkui ^b  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b People's Hospital of Zhoushan   (China)

Author keywords

Breast cancer; Estrogen; Estrogen receptor ; Nuclear factor B; Toll like receptor 9

Indexed keywords

3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; CPG OLIGODEOXYNUCLEOTIDE; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TOLL LIKE RECEPTOR 9 AGONIST; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RNA INTERFERENCE;

BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOPRECIPITATION; NF-KAPPA B; POLYMERASE CHAIN REACTION; RESPONSE ELEMENTS; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 9; TRANSCRIPTIONAL ACTIVATION; TRANSFECTION;

EID: 70350359432     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000520     Document Type: Article

References (36)

1. Akira S and Hemmi H: Recognition of pathogen-associated molecular patterns by TLR family. Immunol Lett 85: 85-95, 2003.
2. Leifer CA, Kennedy MN, Mazzoni A, Lee C, Kruhlak MJ and Segal DM: TLR9 is localized in the endoplasmic reticulum prior to stimulation. J Immunol 173: 1179-1183, 2004.
3. Wagner H: The immunobiology of the TLR9 subfamily. Trends Immunol 25: 381-386, 2004.
4. Evans RM: The steroid and thyroid hormone receptor superfamily. Science 240: 889-895, 1998.
5. Persson IJ: Estrogens in the causation of breast, endometrial and ovarian cancers - evidence and hypotheses from epidemiological findings. J Steroid Biochem Mol Biol 74: 357-364, 2002.
6. Tsai MJ and O'Malley BW: Molecular mechanisms of action of steroid/ thyroid receptor superfamily members. Annu Rev Biochem 63: 451-486, 1994.
7. Yue W, Wang JP, Li Y, Bocchinfuso WP, Korach KS, Devanesan PD, Rogan E, Cavalieri E and Santen RJ: Tamoxifen versus aromatase inhibitors for breast cancer prevention. Clin Cancer Res 11: 925s-930s, 2005.
8. Chan S: A review of selective estrogen receptor modulators in the treatment of breast and endometrial cancer. Semin Oncol 29: 129-133, 2006.
9. Zaks-Zilberman M, Zaks TZ and Vogel SN: Induction of proinflammatory and chemokine genes by lipopolysaccharide and paclitaxel (Taxol) in murine and human breast cancer cell lines. Cytokine15: 156-165, 2001.
10. Merrell MA, Ilvesaro JM, Lehtonen N, et al: Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity. Mol Cancer Res 4: 437-447, 2006.
11. Zhou R, Norton JE, Zhang N and Dean DA: Electroporation-mediated transfer of plasmids to the lung results in reduced TLR9 signaling and inflammation. Gene Ther 14: 775-780, 2007.
12. Brunnberg S, Pettersson K, Rydin E, Matthews J, Hanberg A and Pongratz I: The basic helix-loop-helix-PAS protein ARNT functions as a potent coactivator of estrogen receptor-dependent transcription. Proc Natl Acad Sci USA 100: 6517-6522, 2003.
13. Delaunay F, Pettersson K, Tujague M and Gustafsson JA: Functional differences between the amino-terminal domains of estrogen receptors alpha and beta. Mol Pharmacol 58: 584-590, 2000.
14. Sun H, Li N, Wang X, et al: Molecular cloning and characterization of a novel cystatin-like molecule, CLM, from human bone marrow stromal cells. Biochem Biophys Res Commun 301: 176-182, 2003.
15. Fan M, Nakshatri H and Nephew KP: Inhibiting proteasomal proteolysis sustains estrogen receptor-α activation. Mol Endocrinol 18: 2603-2615, 2004.
16. Ilvesaro JM, Merrell MA, Li L, et al: Toll-like receptor 9 mediates CpG oligonucleotide-induced cellular invasion. Mol Cancer Res 6: 1534-1543, 2008.
17. Matthews J, Wihlén B, Tujague M, Wan J, Ström A and Gustafsson JA: Estrogen receptor (ER) beta modulates ERalpha-mediated transcriptional activation by altering the recruitment of c-Fos and c-Jun to estrogen-responsive promoters. Mol Endocrinol 20: 534-543, 2006.
18. Peng X, Mehta R, Wang S, Chellappan S and Mehta RG: Prohibitin is a novel target gene of vitamin D involved in its antiproliferative action in breast cancer cells. Cancer Res 66: 7361-7369, 2006.
19. Yager JD and Davidson NE: Estrogen carcinogenesis in breast cancer. N Engl J Med 354: 270-282, 2006.
20. Evans MJ, Eckert A, Lai K, Adelman SJ and Harnish DC: Reciprocal antagonism between estrogen receptor and NF-κB activity in vivo. Circ Res 89: 823-830, 2001.
21. Coussens LM and Werb Z: Inflammation and cancer. Nature 420: 860-867, 2002.
22. Krieg AM: Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 5: 471-484, 2006.
23. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K and Akira S: A Toll-like receptor recognizes bacterial DNA. Nature 408: 740-745, 2000.
24. Medzhitov R: Toll-like receptors and innate immunity. Nat Rev Immunol 1: 135-145, 2001.
25. Latz, E, Schoenemeyer A, Visintin A, Fitzgerald KA, Monks BG, Knetter CF, Lien E, Nilsen NJ, Espevik T and Golenbock DT: TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol 5: 190-198, 2004.
26. Dunne A and O'Neill LA: The interleukin-1 receptor/Toll-like receptor superfamily: signal transduction during inflammation and host defense. Sci STKE re3, 2003.
27. Karin M and Ben-Neriah Y: Phosphorylation meets ubiquitination: the control of NF-κB activity. Annu Rev Immunol 18: 621-623, 2000.
28. Harnish DC, Scicchitano MS, Adelman SJ, Lyttle CR and Karathanasis SK: The role of CBP in estrogen receptor cross-talk with nuclear factorkappaB in HepG2 cells. Endocrinology 141: 3403-3411, 2000.
29. Speir E, Yu ZX, Takeda K, Ferrans VJ and Cannon RO: Competition for p300 regulates transcription by estrogen receptors and nuclear factorkappaB in human coronary smooth muscle cells. Circ Res 87: 1006-1011, 2000.
30. Ray A and Prefontaine KE: Physical association and functional antagonism between the p65 subunit of transcription factor NF-kappa B and the glucocorticoid receptor. Proc Natl Acad Sci USA 91: 752-756, 1994.
31. Quaedackers ME, van den Brink CE, van der Saag PT and Tertoolen LG: Direct interaction between estrogen receptor α and NF-κB in the nucleus of living cells. Mol Cell Endocrinol 273: 42-50, 2007.
32. Stein B and Yang MX: Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-kappa B and C/EBP beta. Mol Cell Biol 15: 4971-4979, 1995.
33. Deshpande R, Khalili H, Pergolizzi RG, Michael SD and Chang MD: Estradiol down-regulates LPS-induced cytokine production and NFκB activation in murine macrophages. Am J Reprod Immunol 38: 46-54, 1997.
34. Ray P, Ghosh SK, Zhang DH and Ray A: Repression of interleukin-6 gene expression by 17β-estradiol: inhibition of the DNA-binding activity of the transcription factors NF-IL6 and NF-kappa B by the estrogen receptor. FEBS Lett 409: 79-85, 1997.
35. Sun WH, Keller ET, Stebler BS and Ershler WB: Estrogen inhibits phorbol ester-induced I kappa B alpha transcription and protein degradation. Biochem Biophys Res Commun 244: 691-695, 1998.
36. Ilvesaro JM, Merrell MA, Swain TM, Davidson J, Zayzafoon M, Harris KW and Selander KS: Toll like receptor-9 agonists stimulate prostate cancer invasion in vitro. Prostate 67: 774-781, 2007.